<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35600754</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">2045-1253</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>12</Volume>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>Therapeutic advances in psychopharmacology</Title>
          <ISOAbbreviation>Ther Adv Psychopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The efficacy of antipsychotics in the treatment of physical aggressive behavior in patients with dementia in nursing homes.</ArticleTitle>
        <Pagination>
          <StartPage>20451253221097452</StartPage>
          <MedlinePgn>20451253221097452</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">20451253221097452</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1177/20451253221097452</ELocationID>
        <Abstract>
          <AbstractText>Patients with dementia often suffer from behavioral changes. A common behavioral change is acute physical aggressive behavior which is the most distressing change. This can lead to harm, which is especially problematic in nursing homes. Despite the serious safety concerns, antipsychotics are often prescribed to combat this problem. This article is aimed to review the evidence of the efficacy of utilizing antipsychotics in acutely treating physical aggressive behavior in patients with dementia in nursing homes. Therefore, a systematic literature search was performed. The results demonstrated that a meta-analysis confirmed statistically significant reduction in physical aggression when risperidone was compared to placebo. However, a randomized controlled trial showed no change in physical aggressive behavior between quetiapine and placebo. More research is needed to fully investigate the benefits of physical aggressive behavior and safety concerns of all the antipsychotics in patients with dementia in nursing homes.</AbstractText>
          <CopyrightInformation>© The Author(s), 2022.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nawzad</LastName>
            <ForeName>Sina</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cahn</LastName>
            <ForeName>Wiepke</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abdullah-Koolmees</LastName>
            <ForeName>Heshu</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0003-3789-2383</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Postbus 85500, 3508 GA Utrecht, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ther Adv Psychopharmacol</MedlineTA>
        <NlmUniqueID>101555693</NlmUniqueID>
        <ISSNLinking>2045-1253</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cohen-Mansfield Agitation Inventory (CMAI) scale</Keyword>
        <Keyword MajorTopicYN="N">aggressive behavior</Keyword>
        <Keyword MajorTopicYN="N">antipsychotics</Keyword>
        <Keyword MajorTopicYN="N">dementia</Keyword>
        <Keyword MajorTopicYN="N">neuropsychiatric symptoms</Keyword>
      </KeywordList>
      <CoiStatement>Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>3</Hour>
          <Minute>58</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35600754</ArticleId>
        <ArticleId IdType="pmc">PMC9118396</ArticleId>
        <ArticleId IdType="doi">10.1177/20451253221097452</ArticleId>
        <ArticleId IdType="pii">10.1177_20451253221097452</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Porsteinsson AP, Antonsdottir IM.
An update on the advancements in the treatment of agitation in Alzheimer’s disease. Expert Opin Pharmacother
2017; 18: 611–620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28300462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lin YT, Hwang TJ, Shan JC, et al.. Dosage and duration of antipsychotic treatment in demented outpatients with agitation or psychosis. J Formos Med Assoc
2015; 114: 147–153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25678176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gilley DW, Whalen ME, Wilson RS, et al.. Hallucinations and associated factors in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci
1991; 3: 371–376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1821255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zuidema SU, Johansson A, Selbaek G, et al.. A consensus guideline for antipsychotic drug use for dementia in care homes. Bridging the gap between scientific evidence and clinical practice. Int Psychogeriatr
2015; 27: 1849–1859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4582430</ArticleId>
            <ArticleId IdType="pubmed">26062126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
European Medicines Agency. Risperdal, 2008, https://www.ema.europa.eu/medicines/human/referrals/risperdal (accessed 12 October 2018).</Citation>
        </Reference>
        <Reference>
          <Citation>
Steinberg M, Lyketsos CG.
Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry
2012; 169: 900–906.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3516138</ArticleId>
            <ArticleId IdType="pubmed">22952071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ballard C, Creese B, Corbett A, et al.. Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opin Drug Saf
2011; 10: 35–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20684745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sackett DL, Richardson WS, Rosenberg WM, et al.. Evidence based medicine: how to practice and teach EBM. New York: Churchill Livingstone, 1997.</Citation>
        </Reference>
        <Reference>
          <Citation>
Schulz KF, Altman DG, Moher D, et al.. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med
2010; 7: e1000251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2844794</ArticleId>
            <ArticleId IdType="pubmed">20352064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ
2021; 372: n71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8005924</ArticleId>
            <ArticleId IdType="pubmed">33782057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Drukker M, Weltens I, van Hooijdonk CFM, et al.. Development of a methodological quality criteria list for observational studies: the observational study quality evaluation. Front Res Metr Anal
2021; 6: 675071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8317224</ArticleId>
            <ArticleId IdType="pubmed">34337310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
De Deyn PP, Katz IR, Brodaty H, et al.. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg
2005; 107: 497–508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15922506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brodaty H, Ames D, Snowdon J, et al.. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry
2003; 64: 134–143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12633121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
De Deyn PP, Rabheru K, Rasmussen A, et al.. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology
1999; 53: 946–955.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10496251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Katz IR, Jeste DV, Mintzer JE, et al.. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry
1999; 60: 107–115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10084637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhong KX, Tariot PN, Mintzer J, et al.. Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Curr Alzheimer Res
2007; 4: 81–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17316169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cohen-Mansfield J, Billig N.
Agitated behaviors in the elderly. I. A conceptual review. J Am Geriatr Soc
1986; 34: 711–721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3531296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Meehan KM, Wang H, David SR, et al.. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology
2002; 26: 494–504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11927174</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
